About Apellis Pharmaceuticals, Inc.
https://www.apellis.comApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
CEO
Cedric Francois
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
AVORO CAPITAL ADVISORS LLC
Shares:12.22M
Value:$248.48M
VANGUARD GROUP INC
Shares:9.99M
Value:$203.04M
MORGAN STANLEY
Shares:9.64M
Value:$196.05M
Summary
Showing Top 3 of 328
About Apellis Pharmaceuticals, Inc.
https://www.apellis.comApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $458.58M ▲ | $210.86M ▲ | $215.72M ▲ | 47.04% ▲ | $1.71 ▲ | $227.94M ▲ |
| Q2-2025 | $178.49M ▲ | $197.71M ▼ | $-42.15M ▲ | -23.61% ▲ | $-0.33 ▲ | $-30.09M ▲ |
| Q1-2025 | $166.8M ▼ | $215.76M ▲ | $-92.22M ▼ | -55.29% ▼ | $-0.74 ▼ | $-80.39M ▼ |
| Q4-2024 | $212.53M ▲ | $197.84M ▼ | $-36.35M ▲ | -17.11% ▲ | $-0.29 ▲ | $-24.09M ▲ |
| Q3-2024 | $196.83M | $210.55M | $-57.45M | -29.19% | $-0.46 | $-43.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $479.17M ▲ | $1.06B ▲ | $657.55M ▼ | $401.17M ▲ |
| Q2-2025 | $371.47M ▲ | $821.39M ▲ | $665.09M ▲ | $156.31M ▼ |
| Q1-2025 | $358.39M ▼ | $807.28M ▼ | $643.07M ▼ | $164.22M ▼ |
| Q4-2024 | $416.14M ▲ | $885.05M ▼ | $656.51M ▼ | $228.54M ▼ |
| Q3-2024 | $396.86M | $901.87M | $664.75M | $237.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $215.72M ▲ | $108.47M ▲ | $-148K ▼ | $793K ▼ | $109.14M ▲ | $108.32M ▲ |
| Q2-2025 | $-42.15M ▲ | $4.45M ▲ | $-49K ▼ | $6.56M ▲ | $11.64M ▲ | $4.4M ▲ |
| Q1-2025 | $-92.22M ▼ | $-53.41M ▼ | $-8K ▲ | $274K ▲ | $-52.78M ▼ | $-53.42M ▼ |
| Q4-2024 | $-36.35M ▲ | $19.36M ▼ | $-20K ▼ | $-4M ▼ | $14.38M ▼ | $19.34M ▼ |
| Q3-2024 | $-57.45M | $34.1M | $0 | $2.54M | $36.81M | $34.1M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Licensing And Other Revenue | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ | $280.00M ▲ |
 Product | $190.00M ▲ | $150.00M ▼ | $170.00M ▲ | $180.00M ▲ |
CEO
Cedric Francois
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
AVORO CAPITAL ADVISORS LLC
Shares:12.22M
Value:$248.48M
VANGUARD GROUP INC
Shares:9.99M
Value:$203.04M
MORGAN STANLEY
Shares:9.64M
Value:$196.05M
Summary
Showing Top 3 of 328